Evicenter
MarkdownMedical informationP&T meetings
Lonimecgene renparvovec (TSHA-102)

Rett syndrome

Launch
Not announced
Last updated
199 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Glycine-Proline-Glutamate analogs

14 evidence topics · 13 sources

LAVENDER phase 3 trial: co-primary efficacy results at week 12
MeasureTrofinetide (N=93)Placebo (N=94)
RSBQ mean baseline score (SE)“43.7 (1.21)”“44.5 (1.26)”
RSBQ mean week 12 score (SE)“39.9 (1.38)”“42.8 (1.42)”
RSBQ LS mean change from baseline to week 12 (SE)“-4.9 (0.94)”“-1.7 (0.90)”
CGI-I mean week 12 score (SE)“3.5 (0.08)”“3.8 (0.06)”
EndpointTrofinetide-placebo treatment difference, LS mean (95% CI)p-value
RSBQ total score change from baseline“-3.2 (-5.7, -0.6)”“0.018”
CGI-I score at week 12“-0.3 (-0.5, -0.1)”“0.003”
LAVENDER phase 3 trial: adverse reactions in the prescribing information
Adverse reactionTrofinetide (N=93), %Placebo (N=94), %
Diarrhea“82”“20”
Vomiting“29”“12”
Fever“9”“4”
Seizure“9”“6”
Anxiety“8”“1”
Decreased appetite“8”“2”
Fatigue“8”“2”
Nasopharyngitis“5”“1”